n

io
rs
Ve
ed
at
pd
U

LATEST PHARMA DRUGS

NEET PG / NEXT PG / INI CET / FMGE

2022

With from www.medicoapps.org

Is Revision Your Biggest Challenge ?

Top Rated 4.5 out of 5 on Google Playstore

and used by more than 1,00,000 Doctors

Daily Updates on High Yield Topics Join

Video Lectures / Quizzes on Email Subscribe

Live Classes + MCQ Disucssion Subscribe

Clinical Images + Reel on Insta Follow

Clinical + Image Based Question Join

NEET PG / NeXT PG / FMGE

Q Bank / Test Series / Video Lecture Pack
For Special Discounts / Offers
94947 38000
 Latest Drugs in Pharmacology
[NEET PG /NeXT / INI CET / FMGE]

1. Ripretinib
→ Broad-spectrum KIT & PDGFRα inhibitor)
→ Treatment of patients with advanced gastrointestinal stromal tumor (GIST)
who have received prior treatment with 3 or more kinase inhibitors, including imatinib

2. Selpercatinib
→ Kinase Inhibitor
→ Advanced RET fusion-positive non-small cell lung cancer (NSCLC),
→ RET-mutant medullary thyroid cancer (MTC)
→ RET fusion-positive thyroid cancer

3. Capmatinib
→ Kinase inhibitor
→ Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC),
→ Whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET)
exon 14 skipping as detected by an FDA-approved test.

4. Celecoxib
→ Oral solution formulation
→ Non-steroidal anti-inflammatory drug.
→ Acute treatment of migraine with or without aura in adults.

5. Daratumumab & Hyaluronidase

→ Combination of daratumumab, a CD38-directed cytolytic
→ Antibody & hyaluronidase, an endoglycosidase.
→ Treatment of adult patients with multiple myeloma.

6. Leuprolide acetate Inj.

→ Gonadotropin releasing hormone (GnRH) agonist
→ Pediatric patients 2 years of age & older with central precocious puberty.

7. Opicapone
→ Catechol-O-methyltransferase (COMT) inhibitor
→ Adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes

8. Meningococcal (groups A, C, Y, W) conjugate vaccine

→ MenACWY vaccine
→ Active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis
serogroups A, C, W, and Y in individuals 2 years of age and older.
9. Sacituzumab govitecan-hzi
→ Trop-2-directed antibody & topoisomerase inhibitor conjugate
→ Treatment of patients with previously-treated metastatic triple-negative breast cancer (mTNBC).

10. Tucatinib
→ Kinase inhibitor indicated in combination with trastuzumab & capecitabine
→ Treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer.

11. Pemigatinib
→ Selective fibroblast growth factor receptor (FGFR) inhibitor
→ Treatment of locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements,
as detected by an FDA-approved test.

12. Ephedrine sulfate

→ Ready-to-use formulation of approved pressor agent ephedrine
→ Treatment of clinically important hypotension occurring in the setting of anesthesia.

13. Mitomycin
→ Novel formulation of approved alkylating drug
→ Treatment of low-grade upper tract urothelial cancer (LG-UTUC).

14. Selumetinib
→ Mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)
→ Treatment of neurofibromatosis type 1 (NF1), who have symptomatic,
→ Inoperable plexiform neurofibromas (PN), mainly pediatric patients (2yrs & older).

15. Coagulation factor VI a (recombinant)-jncw

→ Coagulation factor VII a concentrate
→ Treatment & control of bleeding episodes - hemophilia A or B with inhibitors (neutralizing antibodies),
occurring in adults & adolescents (12yrs & older).

16. Ozanimod
→ Sphingosine 1-phosphate receptor modulator
→ Treatment of relapsing multiple sclerosis (MS).

17. Osilodrostat
→ Cortisol synthesis inhibitor
→ Treatment of Cushing’s disease (adults).

18. Bimatoprost Implant

→ Prostaglandin analog
→ Reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension (OHT).

19. Isatuximab-irfc
→ CD38-directed cytolytic antibody. In combination with pomalidomide & dexamethasone
→ Treatment of multiple myeloma in adults.

2
20. Ibuprofen & acetaminophen
→ Nonsteroidal anti-inflammatory drug (NSAID)
→ Over-the-counter (OTC) fixed-dose combination of ibuprofen (the nonsteroidal anti-inflammatory drug
(NSAID) contained in Advil)
→ Acetaminophen (the active ingredient in Tylenol) for the relief of pain.

21. Cidofovir dihydrate

→ Injectable antiviral medication
→ Treatment of CMV retinitis in adults with acquired immune defeciency syndrome (AIDS)
& without renal dysfunction

22. Dacomitinib
→ Selective & irreversible inhibitor of epidermal growth factor receptor (EGFR).
→ First line treatmrnt of patients with metastatic non-small cell lung cancer (NSCLC)
with EGFR exon 19 deletion or exon 21 L858R substitution mutations

23. Alpelisib
→ Kinase inhibitor
→ Treatment of postmenopausal women & men, with Hormone receptor (HR)-positive,
→ Human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated,
→ Advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.

24. Isavuconazole sulfate

→ Triazole prodrug with broad-spectrum antifungal activity
→ Treatment of Invasive Aspergillosis & Invasive Mucormycosis

25. Azelnidipine
→ Calcium channel blocker.
→ Treatment of Stage I Hypertension

26. Riboflavin Ophthalmic Solution

→ Intended to treat keratoconus and corneal ecstasia following refractive surger

27. Pixantrone 29mg powder for concentrate for solution for infusion
→ Antineoplastic drug, an analogue of Mitoxantrone
→ Indicated as 3rd line & 4th line therapy for the treatment of adult patients wi
multiply relapsed or refractory aggresive Non-Hodgkins B- Cell Lymphomas (NHL)

28. FDC of Bilastine

→ New 2nd generation H1-antihistamine
→ Treatment of allergic rhinitis in adults.

29. Obeticholic acid

→ Semi-synthetic bile acid analogue.
→ Used in combination with ursodeoxycholic acid (UDCA) in adult with an inadequate response to UDCA
or asmonotherapy in adults unable to tolerate UDCA.
→ Treatment of primary biliary Cholangitis/primary biliary cirrhosis.

3
30. (Isavuconazonium sulfate)
→ Antifungal agent
→ Treatment of Invasive Aspergillosis & Invasive Mucormycosis. Only for 18 yrs & older

31. Pemetrexed
→ Branded alternative to Alimta.
→ Chemotherapy medication.
→Treatment of non-squamous non-small cell lung cancer & malignant pleural mesothelioma.

32. Lactitol
→ Osmotic laxative
→ Treatment of chronic idiopathic constipation (CIC) in adults.

33. Ethinyl estradiol & levonorgestrel

→Hormonal Transdermal system
→ Low-dose combined hormonal contraceptive patch for birth control.

34. Meloxicam
→Non-steroidal anti-inflammatory drug (NSAID) injection
→Management of moderate-to-severe pain alone or in combination with non-NSAID analgesics mainly in adults.

35. Bempedoic acid

→Adenosine triphosphate-citrate lyase (ACL) inhibitor & Cholesterol absorption inhibitor combination
→Indicated as an adjunct to diet & maximally tolerated statin therapy for the treatment of adults with
→Heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease,
→Who require additional lowering of LDL-C.

36. Amisulpride
→Dopamine-2 (D2) antagonist
→Management of post-operative nausea & vomiting (PONV).

37. Rimegepant
→Calcitonin gene-related peptide (CGRP) receptor antagonist . Orally Disintegrating Tablets (ODT)
→Acute treatment of migraine.

38. Avapritinib
→Kinase inhibitor
→Treatment of PDGFRα exon 18 mutant gastrointestinal stromal tumors (GIST).

39. Valtoco (diazepam) Nasal Spray

→Benzodiazepine nasal spray
→Short-term treatment of epilepsy cluster seizures.

40. Cocaine hydrochloride

→Local anesthetic
→Introduction of local anesthesia of the mucous membranes for diagnostic procedures & surgeries on
or through the nasal cavities of adults.

4
41. Teprotumumab-trbw
→Human monoclonal antibody (mAb) & a targeted inhibitor of the insulin-like growth factor 1 receptor (IGF-1R)
→Active thyroid eye disease (TED).

42. Tazemetostat
→Methyltransferase inhibitor
→Treatment of epithelioid sarcoma.

43. Empagliflozin, linagliptin & metformin hydrochloride

→Fixed-dose combination of sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance),
the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (Tradjenta) & biguanide metformin hydrochloride
→An adjunct to diet & exercise to improve glycemic control in adults with type 2 diabetes mellitus.

44. Ferric derisomaltose

→Intravenous iron replacement product
→Treatment of iron deficiency anemia.

45. Influenza A (H5N1) monovalent vaccine, adjuvanted

→Monovalent vaccine, adjuvanted - Cell-based influenza vaccine
→Protect against influenza A (H5N1) in the event of a pandemic.

46. Fenspiride hydrochloride

→Oxazolidinone spiro compound
→Acute Rhinosinusitis Moderate persistent asthma as an addon therapy

47. Bilastine
→2nd generation antihistamine medicatio
→For symptomatic treatment of allergic rhino-conjuctivitis (seasonal & perennial) Utricaria in adults

48. Iguratimod
→2nd generation antihistamine medicatio
→For symptomatic treatment of allergic rhino-conjuctivitis (seasonal & perennial) Utricaria in adults

49. Fingolimod
→Immuno-modulators
→Treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of
clinical exacerbations and to delay the accumulation of physical disability

50. Levomilnacipran
→Antidepressant drug
→Treatment of major depressive disorder

51. Solriamfetol
→Norepinephrine–dopamine reuptake inhibitor (NDRI)
→Treatment of excess sleep during daytime in patients with narcolepsy & Obstructive sleep apnea

52. Brexanolone
→Antidepressant drug
→Treatment Of Postpartum Depression
5
53. LumateperoneTosylate
→Antipsychotic Drug
→Treatment Of Schizophrenia

54. Lemborexant
→CNS Depressant
→Treatment Of Insomnia

55. Voxelotor
→Hemoglobin S (HbS) polymerization inhibitors.
→Treatment of Sickle cell anemia

56. Lasmiditan
→Selective serotonin receptor agonists.
→Treatment of Migraine with/without Aura

57. Triclabendazole
→Antihelminthic drug
→Treatment of fascioliasis

58. Pretomanid
→Anti-bacterial agents
→Treatment of multi-drug resistant tuberculosis (MDR-TB)

59. Selinexor
→Chemotherapeutic agent
→Treatment of multi-drug resistant tuberculosis (MDR-TB)

60. Zanubrutinib
→ Chemotherapeutic agent- Kinase Inhibitor
→Treatment of Mantle Cell Lymphoma (MCL)

61. Fedratinib
→Chemotherapeutic agent- Kinase Inhibitor
→Treatment of myelofibrosis in adults

62. Entrectinib
→ Chemotherapeutic agent- Kinase Inhibitor
→Treatment of non-small cell lung cancer (NSCLC)

63. Trifarotene
→Retinoids
→Treatment of Acne vulgaris in adults and children 9 years of age and older.

6
64. Givosiran
→RNAi Agents
→Treatment of acute hepatic porphyria in adults

65. Givosiran
→RNAi Agents
→Treatment of acute hepatic porphyria in adults

66. Upadacitinib
→Immunosuppressants -Janus kinase (JAK) inhibitors
→Treatment of arthritis (such as psoriatic arthritis, rheumatoid arthritis).

67. Ubrogepant
→Calcitonin gene-related peptide receptor antagonists
→Treatment of acute migraine headaches with or without aura

68. Golodirsen
→Synthetic Antisense Oligonucleotide
→Treatment of Duchenne muscular dystrophy in adults and children who have a certain gene mutation.

69. Bremelanotide
→Melanocortin Receptor Agonists
→Treatment of low sexual desire in women who have not gone through menopause and have not had low
sexual desire in the past.

70. Istradefylline
→Melanocortin Receptor Agonists
→Treatment of low sexual desire in women who have not gone through menopause and have not had low
sexual desire in the past.

71. Cenobamate
→Antiepileptic Drug
→Treatment of epilepsy to control partial-onset seizures (convulsions)

72. Caplacizumab-yhdp
→Antithrombotic agents
→Treatment of Acquired thrombotic thrombocytopenic purpura (aTTP)

73. Luspatercept
→Erythroid maturation agents
→Treatment of anemia in adults who are receiving blood transfusions to treat thalassemia

74. Tenapanor
→NHE3 inhibitors
→Treatment of irritable bowel syndrome with constipation

7
75. Romosozumab
→Sclerostin inhibitors
→Treatment of osteoporosis in postmenopausal women

76. Pitolisant
→H3 blockers
→Treatment of excessive daytime sleepiness caused by narcolepsy

77. Cefiderocol
→Cephalosporin antibiotics
→Treatment of Urinary Tract Infections

78. Lefamulin
→Pleuromutilin antibiotics
→Treatment of Community Acquired Pneumonia

79. Erdafitinib
→Kinase inhibitors
→Treatment of Bladder Cancer

80. Darolutamide
→Androgen receptor inhibitors
→Treatment of Prostate Cancer

81. Pexidartinib
→Kinase inhibitors
→Treatment of Tenosynovial Giant Cell Tumor

82. Risankizumab-rzaa
→Monoclonal antibodies
→Treatment of moderate to severe plaque psoriasis

83. Brolucizumab-dbll
→Vascular endothelial growth factor A (VEGF-A) antagonists
→Treatment of wet age-related macular degeneration

84. Betrixaban
→Factor Xa Inhibitor
→Used to prevent blood clots in adults who have a serious illness and decreased ability to move

85. Copanlisib
→Kinase inhibitors
→Treatment of follicular lymphoma

86. Inotuzumab
→Anti-CD22 monoclonal antibody and antineoplastic agent
→Treatment of acute lymphoblastic leukemia

8
87. Enasidenib
→Isocitrate dehydrogenase 2 (IDH2) inhibitor
→Treatment of certain type of blood cell cancer (acute myeloid leukemia-AML)

88. Midostaurin
→Kinase inhibitors
→Treatment of acute myeloid leukemia

89. Naldemedine
→Peripherally acting mu-opioid receptor antagonists
→Treatment of opioid induced constipation

90. Semaglutide
→Glucagon-like peptide 1 (GLP-1)
→To control blood sugar levels in adults with type 2 diabetes

91. Saxagliptin
→Dipeptidyl peptidase-4 (DPP-4) inhibitors
→Treatment of lower blood sugar levels in patients with type 2 diabetes

92. Glecaprevir
→HCV NS3/4A protease inhibitors
→Treatment of chronic (long-term) hepatitis C infection

93. Sofosbuvir
→Nucleotide polymerase inhibitors
→Treatment of certain types of chronic hepatitis C

94. Etelcalcetide
→Calcimimetics
→Treatment of secondary hyperparathyroidism

95. Meropenem
→Beta-lactam antibiotic
→Treatment of complicated urinary tract infections and pyelonephritis caused by susceptible bacteria

96. Deutetrabenazine
→Vesicular monoamine transporter 2 (VMAT2) inhibitors
→Used to decrease involuntary movements (chorea) caused by Huntington's disease.

97. Valbenazine
→Vesicular monoamine transporter 2 (VMAT2) inhibitors
→Treatment of tardive dyskinesia

98. Edaravone
→Antioxidants
→Treatment of amyotrophic lateral sclerosis

9
99. Safinamide
→MAO inhibitors
→Treatment of Parkinson's disease

100. Sarilumab
→Monoclonal antibodies
→Treatment of rheumatoid arthritis

101. Ocrelizumab
→Monoclonal antibodies
→Treatment of Multiple Sclerosis-MS

102. Abemaciclib
→Kinase inhibitors
→Treatment of metastatic breast cancer

103. Neratinib maleate

→Kinase inhibitors
→Treatment of certain types of HER2-positive breast cancer that have already been treated.

104. Ribociclib
→Aromatase Inhibitors
→Treatment of HER2-negative breast cancer

105. Durvalumab
→Monoclonal antibodies
→Treatment of advanced or metastatic urothelial carcinoma

106. Brigatinib
→Kinase inhibitors
→Treatment of non-small cell lung cancer

107. Niraparib
→Poly (ADP-ribose) polymerase (PARP) inhibitors
→Treatment of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer

108. Benralizumab
→Monoclonal antibodies
→Treatment of severe asthma

109. Avelumab
→Monoclonal antibodies
→Treatment of Merkel cell carcinoma

110. Delafloxacin
→Fluoroquinolone
→Treatment of skin infections and certain types of pneumonia

10
111. Dupilumab
→Monoclonal antibodies
→Treatment of Symptoms of eczema

112. Brodalumab
→Monoclonal antibodies
→Treatment of moderate to severe plaque psoriasis

113. Guselkumab
→Monoclonal antibodies
→Treatment of moderate to severe plaque psoriasis

114. Ozenoxacin
→Quinolone
→Treatment of Impetigo

115. Benznidazole
→Antiparasitic drugs
→Treatment of Chagas disease

116. Deflazacort
→Corticosteroids
→Treatment of Duchenne muscular dystrophy (DMD)

117. Secnidazole
→Antibiotics
→Treatment of vaginal infection (vaginosis)

118. Secnidazole
→Abaloparatide
→Human parathyroid hormone-related protein (PTHrP)
→Treatment of bone loss (osteoporosis) for women after menopause who are at high risk of having
broken bones (fractures)

119. Tralokinumab-ldrm
→Monoclonal antibody
→To treat moderate-to-severe atopic dermatitis

120. Inclisiran
→Proprotein convertase subtilisin kexin type 9 (PCSK9)-interfering mRNA
→To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease
as an add-on therapy

11
121. Efgartigimod alfa-fcab
→Neonatal Fc receptor blocker
→To treat generalized myasthenia gravis

122. Tezepelumab-ekko
→Monoclonal antibody
→To treat severe asthma as an add-on maintenance therapy

123. Pafolacianine
→Diagnostic Imaging Agents
→To help identify ovarian cancer lesions

124. Maribavir
→Anti-cytomegalovirus antivirals
→To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond to available
antiviral treatment for CMV

125. Vosoritide
→C type natriuretic peptide (CNP) analogs
→To improve growth in children five years of age and older with achondroplasia and open epiphyses

126. Ropeginterferon alfa-2b-njft

→Interferon
→To treat polycythemia vera

127. Asciminib
→Kinase inhibitors
→To treat Philadelphia chromosome-positive chronic myeloid leukemia

128. Avacopan
→Complement C5a receptor antagonist
→To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis in combination with
standard therapy, including glucocorticoids

129. Maralixibat
→Ileal bile acid transporter inhibitors
→To treat cholestatic pruritus associated with Alagille syndrome

130. Atogepant
→ Calcitonin gene-related peptide receptor antagonists
→To prevent episodic migraines

131. Mobocertinib
→ Antineoplastic
→To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor
exon 20 insertion mutations

12
132. Difelikefalin
→ Kappa opioid receptor agonist
→To treat moderate-to-severe pruritus associated with chronic kidney disease

133. Belzutifan
→Hypoxia-inducible factor inhibitors
→To treat von Hippel-Lindau disease under certain conditions

134. Anifrolumab-fnia
→Type I interferon (type I IFN) receptor antagonist
→To treat moderate-to severe systemic lupus erythematousus along with standard therapy

135. Odevixibat
→Ileal bile acid transporter (IBAT) inhibitors
→To treat Pruritus

136. Belumosudil
→Kinase inhibitors
→To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy

137. Fexinidazole
→Antiparasitic Agents
→To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense

138. Finerenone
→Mineralocorticoid receptor (MR) antagonists
→To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes

139. Aducanumab-avwa
→Monoclonal antibodies
→To treat Alzheimer’s disease

140. Ibrexafungerp
→Antifungal
→To treat vulvovaginal candidiasis

141. Olanzapine
→Atypical antipsychotics
→To treat schizophrenia and certain aspects of bipolar I disorder

142. Infigratinib
→Kinase inhibitors
→To treat cholangiocarcinoma

143. Sotorasib
→KRAS inhibitors
→To treat types of non-small cell lung cancer

13
144. Piflufolastat F 18
→Diagnostic Imaging Agents
→To identify prostate-specific membrane antigen-positive lesions in prostate cancer

145. Pegcetacoplan
→Complement inhibitor
→To treat paroxysmal nocturnal hemoglobinuria

146. Dostarlimab-gxly
→Monoclonal antibodies
→To treat endometrial cancer

147. Viloxazine
→Selective norepinephrine reuptake inhibitors
→To treat attention deficit hyperactivity disorder

148. Dasiglucagon
→Glucagon receptor agonists
→To treat severe hypoglycemia

149. Ponesimod
→Sphingosine l-phosphate receptor modulators
→To treat relapsing forms of multiple sclerosis

150. Tivozanib
→Kinase inhibitors
→To treat renal cell carcinoma

151. Fosdenopterin
→Miscellaneous Therapeutic Agents
→To reduce the risk of mortality in molybdenum cofactor deficiency Type A

152. Casimersen
→Antisense oligonucleotide
→To treat Duchenne muscular dystrophy

153. Trilaciclib
→Kinase inhibitors
→To mitigate chemotherapy-induced myelosuppression in small cell lung cancer

154. Umbralisib
→Kinase inhibitors
→To treat marginal zone lymphoma and follicular lymphoma

155. Tepotinib
→Kinase inhibitors
→To treat non-small cell lung cancer

14